Allergan Puts Up $958M For Migraine Treatment Maker

Law360, New York (January 23, 2013, 12:12 PM EST) -- Specialty drugmaker Allergan Inc. will fork over $958 million for MAP Pharmaceuticals Inc., the company behind a new treatment for migraine headaches, to beef up its offerings aimed at alleviating the ailment, the pair said late Tuesday.

Under the deal's terms, MAP shareholders will receive $25 per share in cash, a 60 percent premium over the stock's Tuesday close. The California companies said they expected to button up the transaction — backed using a mix of on-hand cash and new debt — toward the end of...
To view the full article, register now.